Leadership Changes at Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has made significant strides in enhancing its board of directors with the recent election of Jon Moeller as a new member. This change, deemed effective soon, is poised to bring new insights and perspectives to the important leadership team at Lilly.
Welcome Jon Moeller to the Board
Jon Moeller, currently serving as the chairman, president, and CEO of Procter & Gamble (P&G), has been elected to join Lilly’s board of directors. With over two decades of experience at P&G, Mr. Moeller has led pivotal roles in finance, business strategy, and operations, notably as vice chairman and chief financial officer. His extensive background in guiding P&G’s global operations and market strategies will be invaluable at Lilly.
Commitment to Governance
Moeller's role extends to serving on both the Lilly Audit Committee and the Directors and Corporate Governance Committee. His wealth of experience, particularly in consumer-centric operations, positions him to contribute significantly to Lilly’s ongoing strategic initiatives. Jon's election will be officially presented for shareholder approval at the next annual meeting in May 2026.
Changes on the Board: Karen Walker’s Transition
In addition to welcoming Mr. Moeller, Eli Lilly is preparing for a transition with board member Karen Walker stepping down from her position effective December 31, 2024. Since joining the board in 2018, Walker has provided critical insights and mentoring during a dynamic growth phase for the company.
Valued Contributions
Recognized for her experience in brand management and her strategic acumen, Walker has served on various committees, including Audit and Talent and Compensation. Her leadership experience at companies like Intel and Cisco Systems has enriched discussions regarding technology strategy within the board.
CEO's Acknowledgment
Company chair and CEO, David A. Ricks, expressed his gratitude for Walker’s contributions and guidance over the years. Her transition allows her to maintain a collaborative role with Lilly in digital commercial activities going forward. Ricks noted that while the board will miss Walker’s direct input, the ongoing partnership will continue to drive Lilly’s mission forward in the evolving landscape of medicine.
About Eli Lilly and Company
Lilly is a pioneering global medicine company dedicated to transforming scientific advancements into real-world healing solutions. With a legacy of nearly 150 years, Lilly remains committed to addressing the world's most pressing health challenges through innovative research and development. The company is advancing breakthroughs in diabetes care, obesity treatment, Alzheimer’s disease, autoimmune disorders, and oncology, striving to make life better for millions.
As a leader in biotechnology and other scientific domains, Lilly aims to create accessible and affordable treatments. Through thoughtful and inclusive clinical trials, the company ensures that diverse populations benefit from its discoveries. For further details about Eli Lilly and its initiatives, visit Lilly’s online platforms, or connect with them on social media channels.
Frequently Asked Questions
Who is the new member elected to Eli Lilly's board?
Jon Moeller has been elected as a new member of Eli Lilly's board of directors.
What role will Karen Walker take after her resignation from the board?
Karen Walker will continue to collaborate with Eli Lilly on digital commercial activities following her board resignation.
What is Jon Moeller's background?
Jon Moeller has been with Procter & Gamble for over 20 years and has held several key executive positions.
How long has Karen Walker been on the board?
Karen Walker has served on Eli Lilly's board since 2018.
What are some health challenges Eli Lilly aims to address?
Eli Lilly focuses on diabetes care, obesity treatment, Alzheimer’s disease, autoimmune disorders, and cancer therapies.
